» Articles » PMID: 33294212

A Landscape Analysis of HIV Cure-related Clinical Research in 2019

Overview
Journal J Virus Erad
Date 2020 Dec 9
PMID 33294212
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: In 2018, we surveyed investigators conducting HIV cure-related clinical research, drawing on information from the online listing established by Treatment Action Group (TAG). The purpose of the survey was to facilitate a landscape analysis of the field. In 2019, we fielded a second survey in order to provide updated information and assess any shifts in the landscape.

Methods: Trials and observational studies listed as of August 16, 2019 formed the sample set. Survey questions addressed funding, trial development, recruitment, enrollment, participant demographics, antiretroviral therapy status, HIV reservoir assays, invasive procedures, study completion, data sharing and dissemination plans. A survey was sent to the contact(s) for each study. Supplemental information was collected from clinicaltrials.gov and available presentations/publications of study results.

Results: A total of 97 interventional trials and 36 observational studies were identified, with 30 including analytical treatment interruptions. Total projected enrollment is 13,732 participants, with observational studies contributing the majority (8,325). Most interventional trials are in early phases. The majority of current research is located in the USA, involves predominately male participants and is limited in racial and ethnic diversity. Prespecified demographic enrollment targets are rare. Two thirds of respondents to our previous survey reported that enrollment is progressing more slowly than anticipated.

Conclusions: A diverse range of interventions are being evaluated in HIV cure research, but participant diversity is far from optimal with a continuing underrepresentation of women. Broadening inclusion and geographic reach will be necessary to achieve the goal of developing widely effective, safe and accessible curative interventions.

Citing Articles

Beliefs about HIV cure: A qualitative study of people living with HIV in Soweto, South Africa.

Laher F, Mahlangu N, Sibiya M South Afr J HIV Med. 2025; 26(1):1644.

PMID: 39967752 PMC: 11830836. DOI: 10.4102/sajhivmed.v26i1.1644.


'It is scary to pause treatment': perspectives on HIV cure-related research and analytical treatment interruptions from women diagnosed during acute HIV in Durban, South Africa.

Mthimkhulu D, Dong K, Ngcobo M, Mindry D, Zulu A, Langa N HIV Res Clin Pract. 2025; 26(1):2455917.

PMID: 39862155 PMC: 11829625. DOI: 10.1080/25787489.2025.2455917.


Partner protections in HIV cure-related trials involving analytical treatment interruption: Updated toolkit to mitigate HIV transmission risk.

Dube K, Villa T, Freshwater W, Mauk B, Rid A, Peluso M J Virus Erad. 2024; 10(3):100386.

PMID: 39364082 PMC: 11447310. DOI: 10.1016/j.jve.2024.100386.


Centring the health of women across the HIV research continuum.

Barr E, Marshall L, Collins L, Godfrey C, St Vil N, Stockman J Lancet HIV. 2024; 11(3):e186-e194.

PMID: 38417977 PMC: 11301651. DOI: 10.1016/S2352-3018(24)00004-3.


Participant experiences in HIV cure-directed trial with an extended analytical treatment interruption in Philadelphia, United States.

Bilger A, Plenn E, Barg F, Rendle K, Carter W, Lamour-Harrington A HIV Res Clin Pract. 2023; 24(1):2267825.

PMID: 37837376 PMC: 10634456.


References
1.
Lau J, Smith M, Allan B, Martinez C, Power J, Lewin S . Perspectives on Analytical Treatment Interruptions in People Living with HIV and Their Health Care Providers in the Landscape of HIV Cure-Focused Studies. AIDS Res Hum Retroviruses. 2019; 36(4):260-267. PMC: 7185349. DOI: 10.1089/AID.2019.0118. View

2.
Gossez M, Martin G, Pace M, Ramjee G, Premraj A, Kaleebu P . Virological remission after antiretroviral therapy interruption in female African HIV seroconverters. AIDS. 2018; 33(2):185-197. DOI: 10.1097/QAD.0000000000002044. View

3.
Lelievre J, Hocqueloux L . Unintended HIV-1 Transmission to a Sex Partner in a Study of a Therapeutic Vaccine Candidate. J Infect Dis. 2019; 220(220 Suppl 1):S5-S6. PMC: 6603976. DOI: 10.1093/infdis/jiz012. View

4.
Smeaton L, Kacanek D, Mykhalchenko K, Coughlin K, Klingman K, Koletar S . Screening and Enrollment by Sex in Human Immunodeficiency Virus Clinical Trials in the United States. Clin Infect Dis. 2019; 71(5):1300-1305. PMC: 7442845. DOI: 10.1093/cid/ciz959. View

5.
Ndungu T, McCune J, Deeks S . Why and where an HIV cure is needed and how it might be achieved. Nature. 2019; 576(7787):397-405. PMC: 8052635. DOI: 10.1038/s41586-019-1841-8. View